CDH1 and neoplasm: That is, given increasing mesenchymal character of the tumor is associated with a poor clinical outcome [9–11] as well as increasing vimentin and/or decreasing E-cadherin expression [11–13]; processes associated with these biomarkers should have strong prognostic significance.